


## Cephalexin hydrochloride monohydrate

<b>Cat. No.:</b>	HY-B0200C
<b>CAS No.:</b>	105879-42-3
<b>Molecular Formula:</b>	C <sub>16</sub> H <sub>20</sub> ClN <sub>3</sub> O <sub>5</sub> S
<b>Molecular Weight:</b>	401.87
<b>Target:</b>	Antibiotic; Bacterial; Penicillin-binding protein (PBP)
<b>Pathway:</b>	Anti-infection
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Cephalexin (Cefalexin) hydrochloride monohydrate is a potent, orally active new semisynthetic cephalosporin antibiotic with a broad antibacterial spectrum. Cephalexin (Cefalexin) hydrochloride monohydrate has antibacterial activity against a wide variety of gram-positive and gram-negative bacteria. Cephalexin (Cefalexin) hydrochloride monohydrate targets penicillin-binding proteins (PBPs) to inhibit bacterial cell wall assembly. Cephalexin (Cefalexin) hydrochloride monohydrate is used for the research of pneumonia, strep throat, and bacterial endocarditis, et al <sup>[1][2]</sup> .								
<b>IC<sub>50</sub> &amp; Target</b>	β-lactam								
<b>In Vitro</b>	Cephalexin (Cefalexin) hydrochloride monohydrate (10 µg/mL) disrupts polymer peptidoglycan (PG) biogenesis by inactivating enzymes called penicillin-binding proteins (PBPs) <sup>[1]</sup> . Cephalexin (Cefalexin) hydrochloride monohydrate inhibits a broad spectrum of gram-positive and gram-negative organisms with MIC values of 2, 2, 2, 2, 4, 4.4 and 5.7 µg/mL for Bacillus anthracis, Edwardsiella taFda, Vibrio cholera, Pasteurella multocida, Edwardsiella tarda, Alcaligenes sp and Proteus rettgeri, respectively <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
<b>In Vivo</b>	Cephalexin (Cefalexin) hydrochloride monohydrate (0-50 mg/kg; p.o.; for 3.5 hours) has antibacterial activity in male Swiss-Webster mice with infected bacterial <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
	<table border="1"> <tr> <td>Animal Model:</td> <td>Male Swiss-Webster mice with infected bacterial<sup>[2]</sup></td> </tr> <tr> <td>Dosage:</td> <td>0-50 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Oral administration; for 3.5 hours</td> </tr> <tr> <td>Result:</td> <td>Had antibacterial activity against Streptococcus pyogenes, Streptococcus pneumoniae, Staphylococcus aureus and several gram-negative species mice.</td> </tr> </table>	Animal Model:	Male Swiss-Webster mice with infected bacterial <sup>[2]</sup>	Dosage:	0-50 mg/kg	Administration:	Oral administration; for 3.5 hours	Result:	Had antibacterial activity against Streptococcus pyogenes, Streptococcus pneumoniae, Staphylococcus aureus and several gram-negative species mice.
Animal Model:	Male Swiss-Webster mice with infected bacterial <sup>[2]</sup>								
Dosage:	0-50 mg/kg								
Administration:	Oral administration; for 3.5 hours								
Result:	Had antibacterial activity against Streptococcus pyogenes, Streptococcus pneumoniae, Staphylococcus aureus and several gram-negative species mice.								

### CUSTOMER VALIDATION

- Theranostics. 2022 Jan 1;12(3):1187-1203.

- Chemosphere. 2021, 131417.
- Chemosphere. 2019 Jun;225:378-387.
- J Med Chem. 2021 Sep 21.
- Infect Immun. 2018 May 22;86(6). pii: e00090-18.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

---

- [1]. Cho H, et, al. Beta-lactam antibiotics induce a lethal malfunctioning of the bacterial cell wall synthesis machinery. Cell. 2014 Dec 4;159(6):1300-11.
- [2]. Buck RE, et, al. Cefadroxil, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother. 1977 Feb;11(2):324-30.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA